35 completed, 8 terminated, 6 recruiting, 3 active not recruiting. 57 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 57 | Completed 35, Terminated 8, Recruiting 6, Active not recruiting 3, Not yet recruiting 2, Unknown 2, Suspended 1 |
| Phase 2 | 6 | Recruiting 4, Completed 1, Unknown 1 |
Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies Liposomal Irinotecan Plus Cisplatin - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | National Health Research Institutes, Taiwan | 44 | 2026-12-01 | 2026-11-02 |
| Human ADME Study of [14C]-AZD1390 AZD1390 - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | AstraZeneca | 8 | 2026-06-30 | 2026-06-12 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies BMS-986523, Gemcitabine, Nab-Paclitaxel - Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 252 | 2025-11-25 | 2026-05-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies BC2027 for Injection - Advanced Solid Malignancies | Phase 1 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 180 | 2025-11-24 | 2026-01-26 |
| Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors Engineered mitochondrial vaccine - Advanced Solid Tumor Malignancies, Advanced Solid Malignancies | Phase 1 | Recruiting | West China Hospital | 12 | 2025-05-09 | 2026-03-17 |
| Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) Tiragolumab, Atezolizumab, Radiation Therapy - Advanced Solid Malignancies | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 7 | 2025-04-13 | 2026-10-07 |
| Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib Saruparib, Digoxin, Furosemide - Advanced Solid Malignancies | Phase 1 | Active not recruiting | AstraZeneca | 41 | 2025-03-25 | 2026-10-01 |
| A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies BR115 for injection - Advanced Solid Malignancies | Phase 1 | Suspended | BioRay Pharmaceutical Co., Ltd. | 120 | 2024-02-19 | 2025-11-21 |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies GIM122 - Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 111 | 2023-12-12 | 2026-08-17 |
| Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies AZD5305, Itraconazole - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 16 | 2022-11-07 | 2024-06-18 |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391 - Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 695 | 2022-06-24 | 2026-10-05 |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies Ceralasertib - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 12 | 2022-06-09 | 2024-08-02 |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors PRJ1-3024 - Advanced Solid Tumor, Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | Zhuhai Yufan Biotechnologies Co., Ltd | 267 | 2022-05-30 | 2024-12-17 |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors PRJ1-3024 - Advanced Solid Tumor, Advanced Solid Malignancies | Phase 1 | Active not recruiting | Zhuhai Yufan Biotechnologies Co., Ltd | 39 | 2022-03-31 | 2025-12-15 |
| A Phase I Open-label Study for Subjects With Advanced Malignancies PT01 (Pegtomarginase) - Advanced Solid Malignancies | Phase 1 | Unknown | Athenex, Inc. | 62 | 2021-04-21 | 2021-08-17 |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies CFI-402411, Pembrolizumab - Advanced Solid Malignancies | Phase 1 / Phase 2 | Unknown | Treadwell Therapeutics, Inc | 170 | 2020-08-31 | 2025-05-21 |
| Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies OB318 capsule - Advanced Solid Malignancies | Phase 1 | Terminated | Oneness Biotech Co., Ltd. | 21 | 2020-08-28 | 2026-07-10 |
| A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies YH002 - Advanced Solid Malignancies | Phase 1 | Completed | Eucure (Beijing) Biopharma Co., Ltd | 15 | 2020-04-22 | 2022-07-22 |
| A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies AZD4635 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 10 | 2019-07-04 | 2020-12-08 |
| A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients MEDI9447 (oleclumab) - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 6 | 2018-11-07 | 2019-07-08 |
Showing 20 of 57. Sign in to see all of them.
Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Lung Neoplasms (2) · Lymphoma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Astrocytoma (1) · Carcinoma, Hepatocellular (1) · Diarrhea (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
Neoplasms (10) · Neoplasms by Site (10) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Neoplasms by Histologic Type (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3)
Gemcitabine (3) · Irinotecan (3) · 3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide (2) · AZD4547 (2) · Fulvestrant (2) · Injections (2) · durvalumab (2) · olaparib (2) · pembrolizumab (2) · sapanisertib (2) · vistusertib (2) · (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (1) · 130-nm albumin-bound paclitaxel (1) · 2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydropyrido(4,3-d)pyrimidin-5(6H)-one (1) · 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1)
AstraZeneca (28) · Hanmi Pharmaceutical Company Limited (3) · Bristol-Myers Squibb (2) · Millennium Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (2) · Zhuhai Yufan Biotechnologies Co., Ltd (2) · AHS Cancer Control Alberta (1) · Athenex, Inc. (1) · BioRay Pharmaceutical Co., Ltd. (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Carrick Therapeutics Limited (1) · Eucure (Beijing) Biopharma Co., Ltd (1) · Georgiamune Inc (1) · InnoPharmax Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
United States (18) · Japan (14) · China (7) · United Kingdom (7) · South Korea (6) · Canada (5) · Spain (5) · Taiwan (4) · Germany (3) · Australia (2) · France (2) · Moldova (2) · Netherlands (2) · Romania (2) · Bulgaria (1)
Peter Langmuir, MD (2) · Becker Hewes, MD (1) · Charles Erlichman, M.D. (1) · Chia-Chi Lin, MD (1) · Ching-Liang Ho (1) · Donal Landers, Dr (1) · Dr. Udai Banerji (1) · Ecaterina Dumbrava, MD (1) · Edward Bradley, MD (1) · Elisabeth Oelmann (1) · Frank Neumann, MSD (1)
PMID 22145984, PMID 22843211, PMID 23010851, PMID 23589215, PMID 25342141, PMID 26223436, PMID 28070720, PMID 28601972, PMID 32385714, PMID 32913286, PMID 36270753, PMID 37488191, PMID 37967136, PMID 38086998, PMID 41351730
2009 (2), 2008 (1), 2017 (1), 2023 (1), 2025 (1)